First Oral Medication to Treat Moderate-to-Severe Crohn’s Disease Completes Successful Phase 3 Trial and Earns FDA Approval
Mount Sinai Health SystemBreakthrough study addresses unmet need in the treatment of Crohn’s disease and helps patients into clinical and endoscopic remission